Coya Therapeutics, Inc.
COYANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — |
| Operating income | −$22.6M | −$17.2M | −$7.9M | −$9.8M | −$4.9M |
| Net income | −$21.2M | −$14.9M | −$8.0M | −$12.2M | −$4.9M |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M |
| Equity | $43.0M | $39.6M | $35.6M | −$8.4M | $3.6M |
| EPS (diluted) | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
| Shares out. | 16.7M | 14.5M | 9.9M | 2.6M | 2.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −283.9%
- Net margin
- −267.1%
- Return on equity
- −49.3%
- Return on assets
- −42.5%
- Return on capital (ROCE)
- −51.2%
- Liabilities / assets
- 13.9%
- Debt / equity
- 0.16×
- Book value / share
- $2.57
- Revenue growth (YoY)
- 123.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.24safe
- Accruals / assets
- −21.0%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Dr. Reddy'S Laboratories, Inc.Passive (13G)Mar 12, 2026
- Vanguard Group IncPassive (13G)Jan 30, 2026
- Hirschman OrinPassive (13G)Jan 28, 2026
- Dme Capital Management, LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 818,097 | 4.0 | -0.9% |
| Apr 30, 2026 | 825,568 | 5.7 | +6.9% |
| Apr 15, 2026 | 771,973 | 4.9 | -12.6% |
| Mar 31, 2026 | 882,759 | 5.7 | +6.0% |
| Mar 13, 2026 | 832,386 | 7.2 | -1.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMay 12, 2026
- Results of operations · Other material eventMay 12, 2026
- Director / officer changeApr 2, 2026
- Results of operationsMar 16, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosure · Other material eventJan 30, 2026
- Other material eventJan 20, 2026
- Other material eventJan 8, 2026
- Other material eventDec 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.